JnJ temporarily halts COVID-19 clinical trials

JnJ temporarily halts COVID-19 clinical trials

AstraZeneca received more funding

As the race for a viable COVID-19 vaccine intensifies, companies do their best to make it all happen. But sometimes things don’t go as planned. So it seems to be the case of Johnson & Johnson.

The giant announced that it has temporarily halted the #COVID-19 #vaccine candidate clinical trials because one of the participants got sick.

To review and evaluate the participants, an independent company has been hired. Also, the company’s clinical and safety physicians are being monitored. The company didn't provide further information about the matter due to privacy concerns.

However, J&J is not the first company to halt its clinical trial. In September, AstraZeneca paused the late-stage trials of its vaccine developed with the University of Oxford, after a British participant got sick. But the company overcame the incident, and now, its antibody treatment will be funded with $486 million. The pharma company will receive the money from the Trump Administration’s Operation Warp Speed to provide 100,000 doses. Under the agreement, the government could purchase as much as 1 million doses.

“This agreement with the US Government will help accelerate the development of our long-acting antibody combination, which has the potential to provide immediate and long-lasting effect in both preventing and treating COVID-19 infections. We will be evaluating the LAAB combination in different settings from prophylaxis, to outpatient treatment to hospitalization, with a focus on helping the most vulnerable people,” read CEO Pascal Soriot’s statement.

Following the news, during pre-market trading, JnJ stock price dropped 1.56%. AstraZeneca is trading 0.85% lower.

Read here about Eli Lilly and Gilead!

Sources: thestreet.com, finance.yahoo.com

La información presentada aquí está preparada por CAPEX.com y no pretende constituir un asesoramiento de inversión. La información aquí se proporciona como una comunicación general de marketing con propósitos solo de información, y como tal, no se han preparado de acuerdo con los requisitos legales diseñados para promover la independencia de un estudio de inversión, y no está sujeto a ninguna prohibición para hacer frente con antelación a la diseminación de los análisis de inversión.

Los usuarios / lectores no deben confiar únicamente en la información presentada aquí y deben hacer su propia investigación / análisis leyendo también la investigación subyacente real. El contenido adjunto es genérico y no tiene en cuenta las circunstancias personales, la experiencia de inversión o la situación financiera actual.

Por lo tanto, Key Way Investments Ltd no aceptará ninguna responsabilidad por las pérdidas de los comerciantes debido al uso y el contenido de la información presentada en este documento. El rendimiento pasado no es un indicador confiable de resultados futuros.